Immune response against Mycobacterium tuberculosis: implications for vaccine development.
Tuberculosis remains a major health problem globally. Although this threat would best be controlled by a combination of chemotherapy and vaccination, satisfactory vaccines are not available yet. Rational design of a novel vaccine generation against tuberculosis has become possible on the basis of recent achievements in molecular genetics of the pathogen and immunology of the host. Currently, two different strategies are pursued. First, the subunit vaccine approach attempting to induce efficacious immunity by unique antigens in defined adjuvants. Second, the whole bacterial vaccine approach relying on multiple antigens and built-in adjuvanticity. Time will tell which type of vaccine is best suited for eradication of tuberculosis.
Kaufmann
S H
SH
Department of Immunology, Max Planck Institute for Infection Biology, Monbijoustr. 2, D-10117, Berlin, Germany. kaufmann@mpiib-berlin.mpg.de
Hess
J
J
D001428:Bacterial Vaccines / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000276:immunology*
D001428:Bacterial Vaccines